Cigna confirms not seeking Humana merger - Breaking The News
Download our appPlay StoreApp Store

Cigna confirms not seeking Humana merger

EPA/CJ GUNTHER

Cigna Group disclosed on Monday on its full-year 2024 guidance report that it is not considering a merger with Humana after reports the two companies had renewed discussions of a deal.

"The Cigna Group expects to communicate that the company is not pursuing a combination with Humana Inc. The Cigna Group remains committed to its established M&A criteria and would only consider acquisitions that are strategically aligned, financially attractive, and have a high probability to close," the firm said.

The announcement comes after Cigna and Humana Inc. canceled their merger talks after failing to reach a deal on price, alongside other financial terms.

The company's stock skyrocketed 7.89% at 8:29 am ET, going for $345.00 apiece while Humana Inc.'s slumped by 5.94% to sell for $271.00.

Related Stocks
Humana
Cigna
Related News
Cleveland-Cliffs, Nucor plan $7 billion bid for US Steel
Cleveland-Cliffs Inc. and Nucor Corporation are jointly preparing a $7 billion bid to acquire US Steel, sources revealed to CNBC on Monday.The offer values US Steel shares at approximately $38 each, exceeding their Friday closing price of $34.24. Cleveland-Cliffs would fund the purchase in cash, while Nucor plans to acquire US Steel's Big River Steel subsidiary.The proposed deal follows the White House's decision to block Japan's Nippon Steel from acquiring US...
J&J to buy Intra-Cellular Therapies in $14.6B deal
Johnson & Johnson announced on Monday that it reached an agreement to buy biopharmaceutical company Intra-Cellular Therapies Inc. for around $14.6 billion or $132 per share in cash. J&J said it will fund the deal through a combination of cash on hand and debt and will provide an update on the potential impact of the acquisition on its adjusted earnings per share during the fourth quarter earnings call on January 22.The transaction is expected to be...
GSK to acquire IDRx for up to $1.15 billion
GSK plc announced on Monday that it agreed to acquire the United States biopharmaceutical company IDRx, Inc. for an upfront payment of $1 billion, with a possibility of an additional success-based payment of $150 based on regulatory approval.The acquisition includes a highly selective KIT tyrosine kinase inhibitor (TKI), IDRX-42, which is being developed as a treatment for gastrointestinal stromal tumors (GIST). According to GSK, IDRX-42 demonstrated...
Eli Lilly said to be in talks to buy Scorpion Therapeutics for $2.5B
Eli Lilly and Company is in advanced talks to acquire biotechnology company Scorpion Therapeutics for $2.5 billion, the Financial Times reported on Friday, citing people briefed on the negotiations. According to sources, Eli Lilly would pay Scorpion $1 billion in advance, and in a later phase it would pay up to $1.5 billion if certain performance milestones are achieved. The deal is expected to be closed in the coming days before a healthcare conference in San...

Please observe our Terms of Use. The price information is time delayed to varying extents, but as a rule by 15 minutes or more, according to the regulations of the selected stock exchange and/or licensors and the type of securities.

© 2025 TeleTrader Software GmbH. All rights reserved

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.